The UA’s focus has been on helping people with chronic pain without using narcotics or other addictive drugs.Continue reading
SenesTech, Inc. (NASDAQ: SNES) announced the issuance of its patent on “REDUCING THE REPRODUCTIVE CAPACITY OF MAMMALS.” This intellectual property is a key aspect of ContraPest®, SenesTech’s flagship product that targets the reproductive capabilities of Norway and roof rats . The patent application was filed August 23, 2013, and has been issued on May 3, 2018 with patent number US 9,956,235.
Surgeons at the University of Arizona College of Medicine – Tucson are developing a tool that may make detecting urine blockage simpler for patients.Continue reading
The three-year Arizona Biomedical Research Commission Awards will fund research relating to neuropathic and cancer pain, migraines, opioids, antibiotics, antivirals, sinusitis, obesity, diabetes, Parkinson’s disease, pulmonary disease and pediatric acute-onset neuropsychiatric syndrome.Continue reading
Interfering with the motion of a kinase enzyme might be a new approach for the development of anti-cancer drugsContinue reading
Researchers around the world use publicly available Ivy Glioblastoma Atlas Project to investigate aggressive brain cancer
AZBio, OTEF, and the Healthcare Impact Foundation’s efforts to establish an endowment to support the commercialization of life science innovation in Arizona is featured in the May/June issue of AZ Business Magazine.Continue reading
Regenesis Biomedical, a Scottsdale-based medical device company, has initiated a multi-center, randomized clinical trial assessing the Provant® Therapy System for relieving symptoms of painful diabetic distal symmetric peripheral neuropathy (DSPN).Continue reading